Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 80 of 5804
-
New drug combo aims to outsmart recurring lymphoma
Disease control OngoingFollicular Lymphoma (FL) is the second most common B-cell cancer and the most common type of cancer of lymphocytes. Unfortunately, this disease is incurable with conventional treatment and the disease recurs in almost all patients. This study will assess how safe and effective ep…
Phase: PHASE3 • Sponsor: Genmab • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New pill could offer hope for advanced breast cancer patients
Disease control Recruiting nowThis is a randomized, parallel-controlled, open-label, multicenter clinical study to assess the efficacy and safety of D-0502 in the treatment of subjects with ER-positive, HER2-negative locally advanced or metastatic breast cancer with fulvestrant injection as a control drug.
Phase: PHASE3 • Sponsor: InventisBio Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Promising antibody added to standard chemo for tough childhood cancer
Disease control Recruiting nowThis is a prospective, multicenter clinical trial in subjects with newly diagnosed high-risk neuroblastoma to evaluate the efficacy and safety of administering naxitamab with standard induction therapy. The initial chemotherapy will include 5 cycles of multi-agent chemotherapy. N…
Phase: PHASE2 • Sponsor: Giselle Sholler • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Could a targeted pill boost chemo for tough blood cancer?
Disease control Recruiting nowA Randomized, Placebo-Controlled Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Adult Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts-2
Phase: PHASE3 • Sponsor: University of Ulm • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New combo therapy aims to keep ovarian cancer at bay longer
Disease control Recruiting nowThis is an international, multicenter, randomized, open, Phase III trial to evaluate the efficacy and safety of carboplatin/paclitaxel/bevacizumab followed by bevacizumab and niraparib compared to carboplatin/paclitaxel followed by niraparib in patients with newly diagnosed advan…
Phase: PHASE3 • Sponsor: AGO Study Group • Aim: Disease control
Last updated Jun 26, 2026 15:26 UTC
-
New hope for myeloma patients: drug combo aims to prevent relapse after transplant
Disease control Recruiting nowThis is a multicenter, randomized, open-label, Phase 3 study in participants with newly diagnosed multiple myeloma to evaluate the benefits of teclistamab in combination with lenalidomide and teclistamab alone versus lenalidomide alone as maintenance therapy after autologous stem…
Phase: PHASE3 • Sponsor: European Myeloma Network B.V. • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Immunotherapy combo aims to stall advanced bladder cancer
Disease control TerminatedThe study is being conducted to evaluate the efficacy and safety of Toripalimab Injection in combination with chemotherapy compared to placebo in combination with chemotherapy in subjects with PD-L1-positive unresectable locally advanced or metastatic urothelial carcinoma who hav…
Phase: PHASE3 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
New needle treatment could replace surgery for curing Hormone-Driven high blood pressure
⭐️ CURE ⭐️ OngoingThe primary objective of WAVE is to test the hypothesis that thermal ablation (microwave or RFA) is non-inferior to surgery in the biochemical (and if so, in the clinical) cure of unilateral PA, according to the international consensus PASO criteria. Secondary objectives are to …
Phase: NA • Sponsor: Queen Mary University of London • Aim: ⭐️ CURE ⭐️
Last updated Jul 19, 2026 00:00 UTC
-
Cancer-Killing virus shows promise in tough ovarian cancer trial
Disease control Recruiting nowThe OnPrime study is a multi-center, randomized open-label phase 3 study evaluating the safety and efficacy of Olvi-Vec followed by platinum-doublet chemotherapy and bevacizumab compared to the Active Comparator Arm with Physician's Choice of chemotherapy and bevacizumab in women…
Phase: PHASE3 • Sponsor: Genelux Corporation • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Gene-Editing breakthrough? new therapy aims to stop sickle cell pain crises
Disease control OngoingThis is an open-label, single-arm, multicenter, Phase 1/2 study evaluating the safety and efficacy of the administration of autologous base edited CD34+ HSPCs (BEAM-101) in patients with severe SCD
Phase: PHASE1, PHASE2 • Sponsor: Beam Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New drug aims to stop relapses in rare brain disease
Disease control OngoingThe main objective of this study is to evaluate the efficacy of satralizumab compared with placebo based on time from randomization to the first occurrence of an adjudicated MOGAD relapse in the double-blind (DB) treatment period. Participants who experience an adjudicated relaps…
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New drug aims to stop liver failure in NASH patients
Disease control OngoingThis study will determine the effect of oral 80 mg resmetirom administered once daily on participants with well-compensated non-alcoholic steatohepatitis (NASH) cirrhosis by measuring the time to experiencing a Composite Clinical Outcome event.
Phase: PHASE3 • Sponsor: Madrigal Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New drug cocktail shows promise for tough childhood leukemia
Disease control OngoingThis is a phase I/II clinical trial evaluating the activity of combination chemotherapy with venetoclax and navitoclax in children with relapsed or refractory acute lymphoblastic leukemia or lymphoma (rALL) and assessing the combination dose of venetoclax combinations with either…
Phase: PHASE1, PHASE2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
One shot of radiation could replace weeks of treatment for some breast cancers
Disease control Recruiting nowIn this ABLATIVE-2 trial, low-risk breast cancer patients will be treated with MRI-guided single dose preoperative partial breast radiotherapy to assess the rate of pathologic complete response after an interval of six to twelve months between radiotherapy and surgery. Response m…
Phase: NA • Sponsor: Amsterdam UMC, location VUmc • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Could a shot every 4 weeks replace weekly blood filtering for High-Risk heart patients?
Disease control CompletedPhase III study to test the hypothesis that treatment with pelacarsen (TQJ230) 80 mg Q4W compared to placebo significantly reduces the rate of lipoprotein apheresis in patients with hyperlipoproteinemia (a) and established cardiovascular disease currently undergoing lipoprotein a…
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New Dual-Targeting CAR-T therapy shows promise for tough lymphoma
Disease control OngoingThis is a Phase 1b/2, multicenter, open-label, study of prizloncabtagene autoleucel (prizlo-cel), an autologous dual targeting chimeric antigen receptor (CAR) T-cell therapy targeting both cluster of differentiation (CD) CD20 and CD19, for the treatment of adult participants with…
Phase: PHASE1, PHASE2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New aspiration tubing aims to restore blood flow faster in major strokes
Disease control CompletedThe objective of this study is to demonstrate the safety and efficacy of the Penumbra System including Thunderbolt Aspiration Tubing (Thunderbolt) in a population presenting with acute ischemic stroke (AIS) secondary to intracranial large vessel occlusion (LVO) who are eligible f…
Phase: NA • Sponsor: Penumbra Inc. • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New vaccine-like shot aims to stop breast cancer recurrence in high-risk patients
Disease control Recruiting nowThis is a prospective, randomized, double-blinded, placebo-controlled, multi-center, Phase 3 study of GLSI-100 immunotherapy in HLA-A\*02 positive and HER2/neu positive subjects who are at high risk for disease recurrence and have completed both neoadjuvant and postoperative adju…
Phase: PHASE3 • Sponsor: Greenwich LifeSciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Could a new immunotherapy stop smoldering myeloma before it becomes active cancer?
Disease control Recruiting nowThe purpose of this study is to test the anti-cancer activity of Teclistamab and to compare it with Lenalidomide + Dexamethasone combination in people with high risk smoldering multiple myeloma. People with smoldering multiple myeloma (SMM) usually do not have symptoms but are a…
Phase: PHASE2 • Sponsor: Irene Ghobrial, MD • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New drug aims to free severe asthma patients from daily steroids
Disease control TerminatedA Randomised, Double-Blind, Parallel-Group, Placebo-Controlled 28-week Phase 3 Efficacy and Safety Study of Tezepelumab in Reducing Oral Corticosteroid Use in Adults with Oral Corticosteroid Dependent Asthma
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC